Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935256 | 0.99 | SIGMAR1 (0.51) | SIGMAR1CHRNA7HRH3PDE2ACYP2A6 | |
| SCHEMBL5935243 | 0.94 | SIGMAR1 (0.43) | SIGMAR1CHRNA7CYP2A6ASIC3LOXL2 | |
| SCHEMBL5935218 | 0.93 | SIGMAR1 (0.44) | SIGMAR1CHRNA7CYP2A6ASIC3LOXL2 | |
| SCHEMBL5935212 | 0.77 | SIGMAR1 (0.66) | SIGMAR1HRH3SLC6A4 | |
| SCHEMBL5935285 | 0.77 | CHRNA7 (0.47) | CHRNA7HRH3PDE2ACYP2A6ASIC3 | |
| Isopropyl Alcohol SCHEMBL4850277 | 0.75 | CYP2A6 (0.46) | HRH3CYP2A6ASIC3LOXL2DRD2 | |
| SCHEMBL5935295 | 0.74 | CHRNA7 (0.55) | SIGMAR1CHRNA7HRH3PDE2ACYP2A6 | |
| SCHEMBL5935223 | 0.74 | CHRNA7 (0.55) | SIGMAR1CHRNA7HRH3PDE2ACYP2A6 | |
| SCHEMBL5935257 | 0.73 | HTR1A (0.54) | SIGMAR1CHRNA7HRH3PDE2ACYP2A6 | |
| SCHEMBL10238584 | 0.72 | FAAH (0.56) | SIGMAR1PDE2ACYP2A6ASIC3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004036-A1 | Sigma-2 receptor agonists and their use in the treatment of HIV infection | THE UNITED STATES OF AMERICA, PER SECY. DHHS, NIH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2004064775-A2 | SIGMA-2 RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF HIV INFECTION | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-05 | — | — | WO | disclosed |
| US-5656625-A | ANTIISCHEMIC AGENT, PSYCHOLOGICAL DISORDER, ANTICONVULSANT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-12 | — | — | US | disclosed |
| US-5346908-A | Anticonvulsant | NATIONAL INSTITUTES OF HEALTH (US) | 1994-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004036-A1 | Sigma-2 receptor agonists and their use in the treatment of HIV infection | TMEM97, SIGMAR1, CNR1 | SIGMAR1 2/4885CHRNA7 456/4885HRH3 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.